Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 2/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 5/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 6/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | HTR3A | P46098 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | MTTP | P55157 | 1/20 | 0.33 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.33 |
| ▸ | MCHR2 | Q969V1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL769370 | 0.92 | HDAC6 (0.33) | SLC2A1ADRB2CHRM3MCHR1DRD4 | |
| SCHEMBL768998 | 0.91 | HTR2A (0.35) | CHRM2 | |
| SCHEMBL768057 | 0.91 | TRPV4 (0.37) | SLC2A1ADRB2CHRM3MCHR1DRD4 | |
| SCHEMBL769264 | 0.89 | CHRM2 (0.39) | SLC2A1ADRB2CHRM3MCHR1CHRM2 | |
| SCHEMBL768889 | 0.87 | CHRM2 (0.39) | SLC2A1ADRB2CHRM3MCHR1CHRM2 | |
| SCHEMBL769140 | 0.86 | CHRM2 (0.36) | SLC2A1ADRB2CHRM3MCHR1CHRM2 | |
| SCHEMBL768103 | 0.85 | HRH3 (0.41) | SLC2A1CHRM3CHRM2 | |
| SCHEMBL768449 | 0.85 | DRD2 (0.38) | SLC2A1ADRB2CHRM3MCHR1HTR3A | |
| SCHEMBL380962 | 0.85 | SLC2A1 (0.52) | SLC2A1ADRB2CHRM3CHRM2 | |
| SCHEMBL768439 | 0.84 | CHRM2 (0.39) | SLC2A1ADRB2CHRM3MCHR1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071467-A1 | AMIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071467-A1 | AMIDE DERIVATIVE | CHRM3, CHRM2, TACR2 | SLC2A1 1942/4885ADRB2 47/4885CHRM3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.